A study conducted by Liu et al. [103] produced an anti-tumor vaccine in which a MUC1 glycopeptide was used as the target tumor-associated immunogen, the α-galactosylceramide (α-GalCer) acted as an immune adjuvant, and gold-based NPs (AuNPs) as the multivalent carriers. This evidence concerns the gene MUC1 and neoplasm.